Video

Bridging the Researcher-Patient Gap

Author(s):

Karuppiah Kannan

Karuppiah Kannan, associate director at Takeda Pharmaceuticals, discusses what it was like as a researcher to meet with patients during the Moving Mountains for Multiple Myeloma Grand Canyon hike.

Karuppiah Kannan, associate director at Takeda Pharmaceuticals, discusses what it was like as a researcher to meet with patients during the Moving Mountains for Multiple Myeloma Grand Canyon hike.

Patients and researchers are on two ends of the treatment spectrum, who, though they rarely meet, cannot exist without the other.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Related Content
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
April 11th 2025

What Role May ctDNA Have in Melanoma Management?

Dr. Michael K. Wong
CURE spoke with Dr. Michael K. Wong and Dr. Diwakar Davar about the use of ctDNA for patients with melanoma, and where the field may be headed.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Image of plasma cells.
April 4th 2025

Overcoming Challenges and Advancing CAR-T Therapy for Myeloma

Spencer Feldman
CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials.
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Dr. Surbhi Sidana discussed the topic of minimal residual disease: nobeastsofierce - stock.adobe.com
April 1st 2025

What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?

Alex Biese
Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.
Illustration of cells.
March 27th 2025

Quadruplet Regimen Preferable to Triplets in Multiple Myeloma

Alex Biese
Dr. Cesar Rodriguez discussed treatment advancements for multiple myeloma during a CURE Educated Patient® Summit.